These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 28890184)

  • 21. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative contrast-enhanced ultrasound evaluation of pathological complete response in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy.
    Wan CF; Liu XS; Wang L; Zhang J; Lu JS; Li FH
    Eur J Radiol; 2018 Jun; 103():118-123. PubMed ID: 29803376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Multiparametric MRI Radiomics-Based Nomogram in Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Two-Center study.
    Wang X; Hua H; Han J; Zhong X; Liu J; Chen J
    Clin Breast Cancer; 2023 Aug; 23(6):e331-e344. PubMed ID: 37321954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.
    Bufi E; Belli P; Di Matteo M; Giuliani M; Tumino M; Rinaldi P; Nardone L; Franceschini G; Mulé A; Bonomo L
    Clin Breast Cancer; 2016 Dec; 16(6):e193-e201. PubMed ID: 27431459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new algorithm for automatic vascular mapping of DCE-MRI of the breast: Clinical application of a potential new biomarker.
    Vignati A; Giannini V; Carbonaro LA; Bertotto I; Martincich L; Sardanelli F; Regge D
    Comput Methods Programs Biomed; 2014 Dec; 117(3):482-8. PubMed ID: 25262335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
    Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
    Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
    Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
    Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
    Kang DK; Kim TH; Han TS; Kim KS; Yim H
    J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging.
    Han X; Yang H; Jin S; Sun Y; Zhang H; Shan M; Cheng W
    Cancer Med; 2023 Jan; 12(2):1389-1398. PubMed ID: 35822639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
    Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computer-aided Diagnosis-generated Kinetic Features of Breast Cancer at Preoperative MR Imaging: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer.
    Kim JJ; Kim JY; Kang HJ; Shin JK; Kang T; Lee SW; Bae YT
    Radiology; 2017 Jul; 284(1):45-54. PubMed ID: 28253106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-Analysis of Quantitative Dynamic Contrast-Enhanced MRI for the Assessment of Neoadjuvant Chemotherapy in Breast Cancer.
    Jun W; Cong W; Xianxin X; Daqing J
    Am Surg; 2019 Jun; 85(6):645-653. PubMed ID: 31267907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-dimensional ultrasonography of the breast; An adequate replacement for MRI in neoadjuvant chemotherapy tumour response evaluation? - RESPONDER trial.
    van Egdom LSE; Lagendijk M; Heijkoop EHM; Koning AHJ; van Deurzen CHM; Jager A; van Lankeren W; Koppert LB
    Eur J Radiol; 2018 Jul; 104():94-100. PubMed ID: 29857873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Discordance in Primary Tumor and Lymph Node Response After Neoadjuvant Therapy in Breast Cancer.
    Fleming CA; McCarthy K; Ryan C; McCarthy A; O'Reilly S; O'Mahony D; Browne TJ; Redmond P; Corrigan MA
    Clin Breast Cancer; 2018 Apr; 18(2):e255-e261. PubMed ID: 29246703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.
    Jensen LR; Garzon B; Heldahl MG; Bathen TF; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2011 Nov; 34(5):1099-109. PubMed ID: 22002757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT.
    An YY; Kim SH; Kang BJ; Lee AW
    J Korean Med Sci; 2015 Jun; 30(6):808-15. PubMed ID: 26028936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results.
    D'Angelo A; Rinaldi P; Belli P; D'Amico R; Carlino G; Grippo C; Giuliani M; Orlandi A; Infante A; Manfredi R
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):225-231. PubMed ID: 30657564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.